and encapsulated bacteria [2] . This choice is highly disputable in terms of practical evaluation of a technique for clinical purposes, since it eliminates its underperforming components. Choices of successive antibiotic therapies were assessed by the clinical microbiologist. However, it is unclear whether all antibiotic therapies were chosen by ID specialists or whether they were chosen by the primary teams before ID specialists were involved in those cases. This could be an important confounder of the assessment of empirical antibiotic therapies. In fact, studies have shown that the choice of antibiotic by ID physicians, compared to those by physicians with other specialties, differed in 50% cases [3] and that their choice tended to be more appropriate, targeting a narrower spectrum [4] . Therefore, assessment of MALDI-TOF's impact could be questionable if there was a bias in the appropriateness of the initial regimen.
Furthermore, the impact of MALDI-TOF on empirical antibiotherapy was compared with the impact of Gram-stain findings. Although we agree with the appropriateness of this choice as the main end point of the study, we believe that the methods would have been greatly improved by using a before-and-after study design. Here, the assessment appears to be flawed because the MALDI-TOF reporting occurred 1 hour after Gram-stain findings were reported. Therefore, it is conceivable that some physicians waited for MALDI-TOF findings were reported before making changes to a current antibiotherapy or starting a new agent, because they knew that more-precise information would be available an hour later. In fact, almost 10% of patients had their empirical antibiotic therapy introduced after MALDI-TOF findings were reported, despite the fact that Gram-stain findings were reported earlier. The lack of information about the percentage of the patients treated by antibiotics before the report of Gram-stain findings and about the appropriateness of empirical antibiotherapies makes it difficult to assess the real impact of MALDI-TOF. Thus, suggesting that MALDI-TOF had an impact on empirical therapy for 35.1% of bacteremias is probably far too optimistic. The real impact may be closer to the value of 11.3% reported by Vlek et al [5] .
It is also important to notice that the above-mentioned studies came from the Netherlands and Switzerland, 2 countries with a low prevalence of extendedspectrum β-lactamase (ESBL) production among Enterobacteriaceae and a greater discipline with regard to antimicrobial stewardship. Therefore, the impact of MALDI-TOF could be stronger in the context of a higher ESBL prevalence. More studies are required to assess the real impact of this tool on antimicrobial choice.
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